Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chronic use of inhaled corticosteroids in patients admitted for respiratory virus infections: a 6-year prospective multicenter study.
Luque-Paz D, Tattevin P, Loubet P, Bénézit F, Thibault V, Lainé F, Vanhems P, Amour S, Lina B, Duval X, L'Honneur AS, Fidouh N, Vallejo C, Alain S, Galtier F, Foulongne V, Lagathu G, Lenzi N, Lesieur Z, Launay O, Jouneau S; FLUVAC Study Group. Luque-Paz D, et al. Among authors: launay o. Sci Rep. 2022 Mar 10;12(1):4199. doi: 10.1038/s41598-022-08089-0. Sci Rep. 2022. PMID: 35273311 Free PMC article.
[Vaccination in patients with cirrhosis].
Loulergue P, Launay O; le groupe GEVACCIM (Groupe d'Etude sur la Vaccination des Sujets Immunodéprimés). Loulergue P, et al. Among authors: launay o. Presse Med. 2009 Jul-Aug;38(7-8):1134-40. doi: 10.1016/j.lpm.2008.11.015. Epub 2009 Jan 29. Presse Med. 2009. PMID: 19185447 Review. French.
Why actively promote vaccination in patients with cirrhosis?
Loulergue P, Pol S, Mallet V, Sogni P, Launay O; GEVACCIM Group. Loulergue P, et al. Among authors: launay o. J Clin Virol. 2009 Nov;46(3):206-9. doi: 10.1016/j.jcv.2009.05.006. Epub 2009 Jun 4. J Clin Virol. 2009. PMID: 19501019 Review.
Questions for biotechs: REIVAC.
Loulergue P, Duval X, Galtier F, Lenzi N, Laurichesse H, Launay O. Loulergue P, et al. Among authors: launay o. Hum Vaccin. 2011 Feb;7(2):142-3. doi: 10.4161/hv.7.2.15130. Hum Vaccin. 2011. PMID: 21937881 No abstract available.
Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial.
Tsatsaris V, Capitant C, Schmitz T, Chazallon C, Bulifon S, Riethmuller D, Picone O, Poulain P, Lewin F, Lainé F, Jacqz-Aigrain E, Aboulker JP, Launay O; Inserm C09-33 PREFLUVAC (Immunogenicity and Safety of an Inactivated Nonadjuvanted A[H1N1v] Influenza Vaccine in Pregnant Women) Study Group. Tsatsaris V, et al. Among authors: launay o. Ann Intern Med. 2011 Dec 6;155(11):733-41. doi: 10.7326/0003-4819-155-11-201112060-00005. Ann Intern Med. 2011. PMID: 22147712 Clinical Trial.
Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.
Laurichesse H, Zimmermann U, Galtier F, Launay O, Duval X, Richard P, Sadorge C, Soubeyrand B. Laurichesse H, et al. Among authors: launay o. Hum Vaccin Immunother. 2012 Dec 1;8(12):1875-81. doi: 10.4161/hv.22083. Epub 2012 Oct 2. Hum Vaccin Immunother. 2012. PMID: 23032160 Free PMC article. Clinical Trial.
499 results